Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Decrease in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 38,895 shares, a drop of 47.6% from the September 15th total of 74,269 shares. Based on an average daily volume of 64,451 shares, the short-interest ratio is presently 0.6 days. Currently, 0.1% of the shares of the company are sold short.

Dogwood Therapeutics Trading Down 3.2%

Shares of DWTX traded down $0.04 during trading hours on Friday, reaching $1.21. 43,511 shares of the company’s stock traded hands, compared to its average volume of 76,403. Dogwood Therapeutics has a 12 month low of $1.18 and a 12 month high of $7.04. The stock has a market cap of $41.13 million, a PE ratio of -0.14 and a beta of 1.92. The firm’s 50 day simple moving average is $1.87 and its 200-day simple moving average is $1.72.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). As a group, analysts expect that Dogwood Therapeutics will post -0.80 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DWTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. HC Wainwright reiterated a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development.